	US 12,226,551 B2
	Drug release coating compositions
Hongxia Zeng, Maple Grove, MN (US); Jonathan Pascal Chaky, Saint Paul, MN (US); Ming Dang, Plymouth, MN (US); and Yen-Lane Chen, New Brighton, MN (US)
Assigned to BOSTON SCIENTIFIC SCIMED, INC., Maple Grove, MN (US)
Filed by BOSTON SCIENTIFIC SCIMED, INC., Maple Grove, MN (US)
Filed on Jul. 30, 2019, as Appl. No. 16/526,912.
Claims priority of provisional application 62/713,081, filed on Aug. 1, 2018.
Prior Publication US 2020/0038559 A1, Feb. 6, 2020
Int. Cl. A61L 31/10 (2006.01); A61K 31/436 (2006.01); A61K 47/34 (2017.01); A61K 47/38 (2006.01); A61L 29/08 (2006.01); A61L 29/16 (2006.01); A61L 31/16 (2006.01)

CPC A61L 29/085 (2013.01) [A61K 31/436 (2013.01); A61K 47/34 (2013.01); A61K 47/38 (2013.01); A61L 29/16 (2013.01); A61L 2300/204 (2013.01); A61L 2300/802 (2013.01); A61L 2420/06 (2013.01)]

14 Claims

1. An elutable coating composition comprising:

an excipient comprising a poly(lactic-co-glycolic acid) (PLGA) having an intrinsic viscosity in the range of about 0.1 deciliters/gram (dL/g) to about 0.8 dL/g;

a binding agent comprising ethyl cellulose; and

a therapeutic agent;

wherein the elutable coating composition maintains a high viscosity with sufficient particle bonding to resist drug loss when exposed to blood flow and reduces the particulate burden in the 25 to 50 micron ranges,

wherein the excipient comprises in the range of about 5 to 40 weight percent of the coating composition.